5-azacytidine
Carcinoma, Non-Small Cell Lung
National Cancer Institute (NCI)Phase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Carcinoma, Non-Small Cell Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sigvotatug Vedotin Pfizer | Phase 3 | BB |
Opnurasib Novartis Pharmaceuticals | Phase 3 | BB |
Sorafenib Bayer | Phase 3 | BB |
SEPANTRONIUM National Cancer Institute (NCI) | Phase 2 | BB |
Tirelizumab Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | BB |
View all 14 →
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →